RxDoctor Payments Data

Anand Haridas, MD

Cardiovascular Disease · Langhorne, PANPI 1457305955

Payments from drug & device makers

$17,083in general payments, 2019–2025

Across 421 payments — averaging $40.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Boston Scientific$1K
  • Sanofi-aventis U.S. LLC$1K
  • AstraZeneca$1K
  • Impulse Dynamics (USA) Inc.$901
  • Novo Nordisk$804
  • plus $6K from 33 others

What the payments were for

  • Speaking & faculty fees$1,0006%
  • Travel & lodging$3,31119%
  • Food & beverage$12,56574%
  • Education$2071%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,083 in reported general payments places this provider in the 80th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$363,983
Medicare patients
1,663
Services billed
4,023

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban201$259,602
XareltoRivaroxaban148$172,782
EntrestoSacubitril/Valsartan89$96,614
FarxigaDapagliflozin Propanediol54$67,635
Repatha SureclickEvolocumab62$47,772
BrilintaTicagrelor34$30,479
WegovySemaglutide20$26,279
JardianceEmpagliflozin15$25,579
VascepaIcosapent Ethyl16$12,937
Metoprolol Succinate498$8,600
Atorvastatin Calcium515$7,526
VerquvoVericiguat11$6,954
Rosuvastatin Calcium312$6,500
Praluent PenAlirocumab12$6,476
Carvedilol ErCarvedilol Phosphate19$6,146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$522$259,602201 claims
Johnson & JohnsonXarelto$465$172,782148 claims
AstraZenecaFarxiga, Brilinta$1,095$98,11488 claims
NovartisEntresto$591$96,61489 claims
Novo NordiskWegovy$804$26,27920 claims
Boehringer IngelheimJardiance$27$25,57915 claims
MerckVerquvo$284$6,95411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Langhorne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →